Dr. Raed Al-Rajabi
Claim this profileHaysMed University of Kansas Health System
Studies Cancer
Studies Colorectal Cancer
10 reported clinical trials
15 drugs studied
Area of expertise
1Cancer
Stage IV
PD-L1 positive
MET positive
2Colorectal Cancer
Stage I
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Raed Al-Rajabi is currently running
SynKIR-110
for Ovarian Cancer
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Recruiting1 award Phase 17 criteria
Temozolomide + Tuvusertib
for Cancer
This trial tests a combination of two drugs, temozolomide and M1774, in patients with advanced cancer that has spread. Temozolomide damages cancer cell DNA, while M1774 blocks growth enzymes. The goal is to find a more effective treatment for these patients.
Recruiting1 award Phase 1 & 2
More about Raed Al-Rajabi
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Raed Al-Rajabi has experience with
- Ipilimumab
- Nivolumab
- Eflornithine
- Sulindac
- ET140203 Autologous T Cell Product
- ECT204 T Cells
Breakdown of trials Raed Al-Rajabi has run
Cancer
Colorectal Cancer
Cholangiocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Raed Al-Rajabi specialize in?
Raed Al-Rajabi focuses on Cancer and Colorectal Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Raed Al-Rajabi currently recruiting for clinical trials?
Yes, Raed Al-Rajabi is currently recruiting for 5 clinical trials in Hays Kansas. If you're interested in participating, you should apply.
Are there any treatments that Raed Al-Rajabi has studied deeply?
Yes, Raed Al-Rajabi has studied treatments such as Ipilimumab, Nivolumab, Eflornithine.
What is the best way to schedule an appointment with Raed Al-Rajabi?
Apply for one of the trials that Raed Al-Rajabi is conducting.
What is the office address of Raed Al-Rajabi?
The office of Raed Al-Rajabi is located at: HaysMed University of Kansas Health System, Hays, Kansas 67601 United States. This is the address for their practice at the HaysMed University of Kansas Health System.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.